Search results
Showing 1906 to 1920 of 2208 results for guidelines
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton.
Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)
Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
based on the scientific evidence assessed by NICE when it produced its guideline on familial breast cancer. There are also diagrams that...
based on the scientific evidence assessed by NICE when it produced its guideline on familial breast cancer. There are also diagrams that...
Discontinued Reference number: GID-TA10072
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Discontinued Reference number: GID-TA10310
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
How we collect and use your personal information, and your rights under data protection legislation.
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .